--- title: "3 Promising Penny Stocks With Market Caps Reaching $300M" type: "News" locale: "en" url: "https://longbridge.com/en/news/288754216.md" description: "Simply Wall St highlights three promising penny stocks with market caps under $300M: Aldeyra Therapeutics (ALDX), Broadwind (BWEN), and Zhihu (ZH). ALDX, a pre-revenue biotech, shows improved net losses despite legal hurdles. BWEN, an infrastructure manufacturer, faces liquidity concerns but has satisfactory debt levels. Zhihu, a Chinese content platform, remains unprofitable but holds a strong cash position exceeding total debt. The article emphasizes balance sheet strength and potential for outsized gains in these niche companies." datetime: "2026-06-04T17:16:59.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288754216.md) - [en](https://longbridge.com/en/news/288754216.md) - [zh-HK](https://longbridge.com/zh-HK/news/288754216.md) --- # 3 Promising Penny Stocks With Market Caps Reaching $300M The market remained flat over the last week, but it is up 26% over the past year, with earnings forecast to grow by 17% annually. Investing in penny stocks—once a buzzword but now more of a niche—can still open doors to growth opportunities, typically in smaller or newer companies. We've identified three penny stocks that combine balance sheet strength with potential for outsized gains, giving investors the chance to discover hidden value in quality companies. Let's uncover some gems from our specialized screener. ## Aldeyra Therapeutics (ALDX) **Simply Wall St Financial Health Rating:** ★★★★☆☆ **Overview:** Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases, with a market cap of $98.93 million. **Operations:** Aldeyra Therapeutics, Inc. does not report any revenue segments. **Market Cap:** $98.93M Aldeyra Therapeutics, a pre-revenue biotech firm with a market cap of US$98.93 million, is navigating several challenges typical of penny stocks. Despite its seasoned board and sufficient cash runway to support operations into 2028, the company faces volatility and legal hurdles. A recent class action lawsuit alleges misleading statements about clinical trial results for its drug candidate reproxalap, which also received an FDA Complete Response Letter questioning its efficacy. However, Aldeyra's reduced net loss from US$9.93 million to US$3.45 million year-over-year indicates some financial improvement amidst these challenges. - Click to explore a detailed breakdown of our findings in Aldeyra Therapeutics' financial health report. - Explore Aldeyra Therapeutics' analyst forecasts in our growth report. ALDX Financial Position Analysis as at Jun 2026 ## Broadwind (BWEN) **Simply Wall St Financial Health Rating:** ★★★★☆☆ **Overview:** Broadwind, Inc. manufactures and sells structures, equipment, and components for power generation and critical infrastructure in the United States, with a market cap of $94.08 million. **Operations:** The company's revenue is primarily derived from three segments: Heavy Fabrications ($92.28 million), Industrial Solutions ($33.84 million), and Gearing ($29.86 million). **Market Cap:** $94.08M Broadwind, Inc., with a market cap of US$94.08 million, is navigating the complexities of the penny stock landscape. The company's recent Q1 2026 earnings report showed sales of US$34.06 million and a net loss of US$0.495 million, reflecting challenges in maintaining revenue growth amidst sector volatility. Despite becoming profitable last year and having satisfactory debt levels, Broadwind's interest coverage remains weak at 0.2x EBIT, and its operating cash flow is negative, indicating potential liquidity concerns. While short-term assets cover liabilities comfortably, high weekly volatility underscores market uncertainty surrounding its financial trajectory. - Navigate through the intricacies of Broadwind with our comprehensive balance sheet health report here. - Examine Broadwind's earnings growth report to understand how analysts expect it to perform. BWEN Debt to Equity History and Analysis as at Jun 2026 ## Zhihu (ZH) **Simply Wall St Financial Health Rating:** ★★★★☆☆ **Overview:** Zhihu Inc. operates an online content community in the People’s Republic of China and has a market cap of approximately $237.97 million. **Operations:** The company generates its revenue primarily from the Internet Information Providers segment, totaling CN¥2.75 billion. **Market Cap:** $237.97M Zhihu Inc., with a market cap of approximately US$237.97 million, continues to face the challenges typical of penny stocks. Despite generating CN¥2.75 billion in revenue primarily from its Internet Information Providers segment, the company remains unprofitable and is not expected to achieve profitability in the next three years. However, Zhihu benefits from a strong cash position that exceeds its total debt and covers both short-term and long-term liabilities comfortably. Recent strategic moves include a share buyback program and changes in board composition, aimed at enhancing shareholder value and corporate governance stability amidst ongoing financial pressures. - Get an in-depth perspective on Zhihu's performance by reading our balance sheet health report here. - Learn about Zhihu's future growth trajectory here. ZH Debt to Equity History and Analysis as at Jun 2026 ## Where To Now? - Unlock more gems! Our US Penny Stocks screener has unearthed 334 more companies for you to explore.Click here to unveil our expertly curated list of 337 US Penny Stocks. - Contemplating Other Strategies? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Valuation is complex, but we're here to simplify it. Discover if Zhihu might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [BWEN.US](https://longbridge.com/en/quote/BWEN.US.md) - [ZH.US](https://longbridge.com/en/quote/ZH.US.md) - [02390.HK](https://longbridge.com/en/quote/02390.HK.md) - [ALDX.US](https://longbridge.com/en/quote/ALDX.US.md) ## Related News & Research - [Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update](https://longbridge.com/en/news/294357729.md) - [Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission](https://longbridge.com/en/news/292816164.md) - [Capricor Therapeutics (NASDAQ:CAPR) Receives Neutral Rating from B. Riley Financial](https://longbridge.com/en/news/293955703.md) - [RA Capital Management reports USD 412,776 Artiva Biotherapeutics common share purchase](https://longbridge.com/en/news/294116655.md) - [Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference | ALDX Stock News](https://longbridge.com/en/news/288411621.md)